BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24756367)

  • 1. Trabectedin: novel insights in the treatment of advanced sarcoma.
    Lopez JP; Gajdos C; Elias A
    Curr Oncol Rep; 2014 Jun; 16(6):387. PubMed ID: 24756367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin therapy for sarcomas.
    Casali PG; Sanfilippo R; D'Incalci M
    Curr Opin Oncol; 2010 Jul; 22(4):342-6. PubMed ID: 20489618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
    Le Cesne A; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Foreword.
    Reichardt P
    Future Oncol; 2015; 11(11 Suppl):1. PubMed ID: 26043309
    [No Abstract]   [Full Text] [Related]  

  • 6. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
    Simpson EL; Rafia R; Stevenson MD; Papaioannou D
    Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
    Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575
    [No Abstract]   [Full Text] [Related]  

  • 9. Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?
    Assi T; Cesne AL
    Future Oncol; 2023 Sep; 19(28):1893-1896. PubMed ID: 37781755
    [No Abstract]   [Full Text] [Related]  

  • 10. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
    Le Cesne A
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of trabectedin for the treatment of liposarcoma.
    Zijoo R; von Mehren M
    Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trabectedin in soft tissue sarcomas.
    Petek BJ; Loggers ET; Pollack SM; Jones RL
    Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Grignani G; MartĂ­n-Broto J; Schuler M; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin for the treatment of soft tissue sarcomas.
    De Sanctis R; Marrari A; Santoro A
    Expert Opin Pharmacother; 2016 Aug; 17(11):1569-77. PubMed ID: 27328277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin's contribution to the treatment of sarcomas.
    Blay JY
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
    Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
    Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
    Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
    Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin in the treatment of metastatic soft-tissue sarcoma: cost-effectiveness and cost-utility are yet to be proved.
    Blomqvist C; Johansson R; Tarkkanen M
    Ann Oncol; 2011 Apr; 22(4):988. PubMed ID: 21345940
    [No Abstract]   [Full Text] [Related]  

  • 19. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
    Gordon EM; Sankhala KK; Chawla N; Chawla SP
    Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study.
    Vincenzi B; Stumbo L; Maltese G; Cerbone L; Spalato Ceruso M; Badalamenti G; Santini D; Tonini G; Frezza AM; De Lisi D; Silletta M
    Sci Rep; 2015 Aug; 5():12077. PubMed ID: 26235506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.